Novo Nordisk presents liver data as analysts rate Novo Nordisk stock Hold

Published on 10/02/2026 at 13:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wegovy cut liver fat from 8.80% to 3.10% after 72 weeks. Novo Nordisk stock costs EUR 33.35 on October 2, 2026, plus 0.15 percent versus EUR 33.30.

Modernes nordisches Forschungszentrum, Glasfassade, Skandinavisches Architekturdesign — Novo Nordisk A/S (DK0062498333): nordisches Forschungszentrum mit Glasfassade und klaren skandinavischen Linien, Illustration mit AI erstellt.

Novo Nordisk (ISIN DK0062498333) presented new Wegovy liver-health data on October 1, 2026, while analysts kept a Hold consensus on Novo Nordisk stock. The company said 88.50 percent of participants with elevated liver fat reached normal levels after 72 weeks in a STEP UP analysis, according to GlobeNewswire.

Wegovy adds a liver-health angle

The analysis covered 55 participants with obesity and elevated liver fat. Among the 26 people whose liver fat exceeded 5 percent at baseline, 23 reached the below-5-percent threshold by week 72, equal to 88.50 percent.

Mean liver fat declined from 8.80 percent at baseline to 3.10 percent after 72 weeks. The company described the analysis as post hoc and exploratory, so the result adds clinical context to Wegovy but does not replace evidence from a dedicated randomized endpoint.

Revenue rose as profit fell

Novo Nordisk reported DKK 78.49 billion of revenue and DKK 20.99 billion of net income for the second quarter of 2026, compared with DKK 76.86 billion and DKK 26.50 billion in the year-earlier quarter, respectively, according to Markets Insider. That combination leaves revenue higher by DKK 1.63 billion while net income is lower by DKK 5.51 billion year over year.

The latest analyst snapshot is cautious. Markets Insider reported on September 29, 2026, that Deutsche Bank maintained a Sell rating and a DKK 245.00 price target, while its cited broader consensus was Hold with a DKK 288.23 average target.

Next results arrive in November

Novo Nordisk is scheduled to announce results for the first three quarters of 2026 on November 4, 2026, at 7:30 a.m. CEST, according to the company financial calendar published on its Novo Nordisk investor-relations page. The date gives investors a defined checkpoint for whether the improved obesity-product outlook is translating into reported growth.

Stock holds near EUR 33

Novo Nordisk was trading at EUR 33.35 at Lang & Schwarz on October 2, 2026, at 1:30 p.m. CEST, up 0.15 percent versus the prior close of EUR 33.30. The primary listing is Nasdaq Copenhagen under the ticker NOVO-B.CO, while the company is classified in health care and pharmaceuticals.

The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.